Status:

RECRUITING

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

Lead Sponsor:

Taizhou Hospital

Collaborating Sponsors:

Taizhou Enze Medical Center Group

Taizhou Cancer Hospital

Conditions:

Nasopharyngeal Carcinoma

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.

Detailed Description

Enrolled patients with complete metabolic response (CMR) and more than 70% partial metabolic response (PMR) according to PERCIST criteria at the 25th fraction will receive intensity modulated radiatio...

Eligibility Criteria

No eligibility criteria provided.

Key Trial Info

Start Date :

January 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2029

Estimated Enrollment :

93 Patients enrolled

Trial Details

Trial ID

NCT04813705

Start Date

January 1 2022

End Date

June 30 2029

Last Update

February 21 2023

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Taizhou Central Hospital

Taizhou, Zhejiang, China, 317000

2

Taizhou Hospital

Taizhou, Zhejiang, China, 317000

3

Taizhou Cancer Hospital

Taizhou, Zhejiang, China, 317500

4

Taizhou Enze Medical Center(Group) Enze Hospital

Taizhou, Zhejiang, China, 318050

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma | DecenTrialz